Market Cap 1.43B
Revenue (ttm) 291.85M
Net Income (ttm) 550,000.00
EPS (ttm) N/A
PE Ratio 133.33
Forward PE 66.67
Profit Margin 0.19%
Debt to Equity Ratio 17.00
Volume 3,753,100
Avg Vol 1,862,196
Day's Range N/A - N/A
Shares Out 172.64M
Stochastic %K 94%
Beta 0.62
Analysts Strong Sell
Price Target $11.29

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatmen...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 844 445 5704
Address:
1375 West Fulton Street, Suite 1300, Chicago, United States
Maissessap
Maissessap Jul. 4 at 5:42 AM
$XERS Management must control the number of free option grants. More than 200k shares, (fully diluted), are way too many shares. Extreme dilution red light is on here.
3 · Reply
gimoozaabi
gimoozaabi Jul. 3 at 8:16 PM
$XERS Happy Long Weekend all
0 · Reply
Maissessap
Maissessap Jul. 3 at 6:51 AM
$XERS They give shares like candy: https://www.investing.com/news/filings/form-4-xeris-pharmaceuticals-inc-for-2-july-93CH-4774546
2 · Reply
BuyThisOne
BuyThisOne Jul. 2 at 8:13 PM
$XERS If we can maintain this price until July 13th they will issue about 4.063 million shares instead of ~4.6 million shares to settle the convertibles. Not all that significant compared to how many they are printing each year but I will take whatever I can get and this price action is nice for a change.
0 · Reply
Fishfearme72
Fishfearme72 Jul. 2 at 7:27 PM
$XERS putting on an early fireworks show! Great week, enjoy the weekend!
0 · Reply
meistermell
meistermell Jul. 2 at 6:57 PM
$XERS Marching on, marching on... https://youtu.be/6BH9HvZx3nI?si=vIwtEvOm7rNfl7rE
0 · Reply
JAAAAAY123
JAAAAAY123 Jul. 2 at 4:25 PM
0 · Reply
joeykool
joeykool Jul. 2 at 4:14 PM
$XERS time for another leg up ??...
1 · Reply
Alon_R
Alon_R Jul. 2 at 4:13 PM
$XERS Really interesting! Not many companies in the world can claim they played a major role in redefining healthcare for such a large patient population. Novo Nordisk did it with injectable Saxenda/Ozempic. Xeris is now entering Phase 3 with XP-8121, a once-weekly injectable levothyroxine. If Phase 3 confirms the Phase 2 results, first ever injectable levothyroxine could be available on or before 2030.
1 · Reply
SportsBetz
SportsBetz Jul. 2 at 4:06 PM
$XERS Seriously though where’s the guy who says he deserves it the most?
0 · Reply
Latest News on XERS
Xeris Announces Updates to Its Board of Directors

Jun 30, 2026, 7:00 AM EDT - 4 days ago

Xeris Announces Updates to Its Board of Directors


Xeris Biopharma Announces Private Exchange of Convertible Notes

Jun 11, 2026, 7:00 AM EDT - 23 days ago

Xeris Biopharma Announces Private Exchange of Convertible Notes


Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026


Xeris Biopharma Holdings Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Xeris Biopharma Holdings Earnings release: Q1 2026


Xeris Biopharma Holdings Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Xeris Biopharma Holdings Quarterly report: Q1 2026


Xeris Biopharma Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 2 months ago

Xeris Biopharma Reports First Quarter 2026 Financial Results


Xeris Biopharma Holdings Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Xeris Biopharma Holdings Proxy statement: Proxy filing


Xeris Biopharma Holdings Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Xeris Biopharma Holdings Proxy statement: Proxy filing


Xeris Biopharma Holdings Slides: Corporate presentation

Mar 4, 2026, 6:00 AM EST - 4 months ago

Xeris Biopharma Holdings Slides: Corporate presentation


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025


Xeris Biopharma Holdings Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Xeris Biopharma Holdings Annual report: Q4 2025


Xeris Biopharma Holdings Earnings release: Q4 2025

Mar 2, 2026, 8:30 AM EST - 4 months ago

Xeris Biopharma Holdings Earnings release: Q4 2025


Xeris Biopharma initiated with an Overweight at Barclays

2025-12-08T21:30:17.000Z - 7 months ago

Xeris Biopharma initiated with an Overweight at Barclays


Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025


Xeris Biopharma Holdings Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Xeris Biopharma Holdings Quarterly report: Q3 2025


Xeris Biopharma Holdings Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Xeris Biopharma Holdings Earnings release: Q3 2025


Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Aug 25, 2025, 7:00 AM EDT - 11 months ago

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®


Xeris Biopharma assumed with a Buy at H.C. Wainwright

2025-08-12T10:10:13.000Z - 11 months ago

Xeris Biopharma assumed with a Buy at H.C. Wainwright


Xeris Biopharma price target raised to $8 from $7 at Oppenheimer

2025-08-08T13:05:44.000Z - 11 months ago

Xeris Biopharma price target raised to $8 from $7 at Oppenheimer


Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025


Xeris Biopharma Holdings Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Xeris Biopharma Holdings Quarterly report: Q2 2025


Xeris Biopharma Holdings Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Xeris Biopharma Holdings Earnings release: Q2 2025


Xeris Biopharma Holdings Transcript: Investor Day 2025

Jun 3, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: Investor Day 2025


Xeris Biopharma Holdings Slides: FY 2025

Jun 3, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Slides: FY 2025


Xeris Announces Details for Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 1 year ago

Xeris Announces Details for Analyst & Investor Day


Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025


Xeris Biopharma Holdings Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Quarterly report: Q1 2025


Xeris Biopharma Holdings Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings release: Q1 2025


Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing


Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing


Xeris Announces Changes to Its Board of Directors

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Xeris Announces Changes to Its Board of Directors


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024


Xeris Biopharma Holdings Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Annual report: Q4 2024


Xeris Biopharma Holdings Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings release: Q4 2024


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 24, 2025, 8:00 AM EST - 1 year ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer


Xeris to Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:00 AM EST - 1 year ago

Xeris to Participate in Upcoming Investor Conferences


Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 10, 2025, 7:00 AM EST - 1 year ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance


Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024


Xeris Biopharma Holdings Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Quarterly report: Q3 2024


Xeris Biopharma Holdings Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings release: Q3 2024


Xeris Biopharma Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results


Xeris Biopharma Holdings Slides: Corporate Presentation

Aug 12, 2024, 6:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Slides: Corporate Presentation


Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024


Xeris Biopharma Holdings Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Quarterly report: Q2 2024


Xeris Biopharma Holdings Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings release: Q2 2024


Xeris Biopharma Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Reports Second Quarter 2024 Financial Results


Xeris Biopharma Announces CEO Succession Plan

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Announces CEO Succession Plan


Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024


Xeris Biopharma Holdings Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Quarterly report: Q1 2024


Xeris Biopharma Holdings Earnings release: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings release: Q1 2024


Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing


Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023


Xeris Biopharma Holdings Annual report: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Annual report: Q4 2023


Xeris Biopharma Holdings Earnings release: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings release: Q4 2023


Maissessap
Maissessap Jul. 4 at 5:42 AM
$XERS Management must control the number of free option grants. More than 200k shares, (fully diluted), are way too many shares. Extreme dilution red light is on here.
3 · Reply
gimoozaabi
gimoozaabi Jul. 3 at 8:16 PM
$XERS Happy Long Weekend all
0 · Reply
Maissessap
Maissessap Jul. 3 at 6:51 AM
$XERS They give shares like candy: https://www.investing.com/news/filings/form-4-xeris-pharmaceuticals-inc-for-2-july-93CH-4774546
2 · Reply
BuyThisOne
BuyThisOne Jul. 2 at 8:13 PM
$XERS If we can maintain this price until July 13th they will issue about 4.063 million shares instead of ~4.6 million shares to settle the convertibles. Not all that significant compared to how many they are printing each year but I will take whatever I can get and this price action is nice for a change.
0 · Reply
Fishfearme72
Fishfearme72 Jul. 2 at 7:27 PM
$XERS putting on an early fireworks show! Great week, enjoy the weekend!
0 · Reply
meistermell
meistermell Jul. 2 at 6:57 PM
$XERS Marching on, marching on... https://youtu.be/6BH9HvZx3nI?si=vIwtEvOm7rNfl7rE
0 · Reply
JAAAAAY123
JAAAAAY123 Jul. 2 at 4:25 PM
0 · Reply
joeykool
joeykool Jul. 2 at 4:14 PM
$XERS time for another leg up ??...
1 · Reply
Alon_R
Alon_R Jul. 2 at 4:13 PM
$XERS Really interesting! Not many companies in the world can claim they played a major role in redefining healthcare for such a large patient population. Novo Nordisk did it with injectable Saxenda/Ozempic. Xeris is now entering Phase 3 with XP-8121, a once-weekly injectable levothyroxine. If Phase 3 confirms the Phase 2 results, first ever injectable levothyroxine could be available on or before 2030.
1 · Reply
SportsBetz
SportsBetz Jul. 2 at 4:06 PM
$XERS Seriously though where’s the guy who says he deserves it the most?
0 · Reply
hassonian
hassonian Jul. 2 at 4:02 PM
$XERS All-time chart looks like a giant cup and handle formation
0 · Reply
Mendryl
Mendryl Jul. 2 at 3:49 PM
$XERS nice move the last few days.
0 · Reply
Nizmeister
Nizmeister Jul. 2 at 3:49 PM
$XERS another FYI to my prior post, its the average price of 21 TRADING days which means the 21 day window ends July 10th (excluding Juneteenth and weekends) so the higher this thing keeps going the lower amount of shares will be given out. Xeris is saving hundreds of thousands of shares with this ongoing run.
0 · Reply
WonderfulMongoose
WonderfulMongoose Jul. 2 at 3:26 PM
$XERS Nothing to see here, move along
1 · Reply
Northwoodspeculator
Northwoodspeculator Jul. 2 at 2:00 PM
$XERS I just compared 1 year charts Of XERS and XBI . XBI was 80 now 160 XERS was just under 5 and is now 8 Oh brother ugh
0 · Reply
BuyThisOne
BuyThisOne Jul. 2 at 1:32 PM
$XERS Also, HALO and CORT have been great about keeping number of shares outstanding low whereas ADMA has a high share count comparably. XERS seems to be headed in the same direction as ADMA and will be something to keep a close eye on. We are at 178 million shares after paying off the convertibles.
0 · Reply
BuyThisOne
BuyThisOne Jul. 2 at 1:16 PM
$XERS If anyone has noticed I can be all over the place with my short term price targets and have a wide range on long targets. If you look at CORT, HALO, ADMA etc. you will begin to understand why I say we could be anywhere from $20-$70 in 2030. HALO is sitting at a PE of 10x while generating huge cashflow while CORT is at PE of 180 with decent cashflow this year but looking to expand quickly moving forward. ADMA is sitting at PE of 10 as the excitement has died down a bit since they hit $23. There are many factors that are going to drive the stock price here over the 5-10 years. Revenue growth, pipeline, additional products, asset acquisition, generic lawsuits, trials, levo potential. I think $40 is a good middle of the road target for 2030 but if they can grow EPS to $2 by then and the market actually becomes excited about levo then $70 seems pretty easy as well. If they aren't able to control expenses or grow revs that is where my $20 bottom of the range comes in.
0 · Reply
NewEra8
NewEra8 Jul. 2 at 12:08 PM
0 · Reply
Ithaca2018
Ithaca2018 Jul. 1 at 10:19 PM
$XERS Princess!
0 · Reply
gimoozaabi
gimoozaabi Jul. 1 at 10:09 PM
$XERS anyone in here In or Monitoring INTS? It’s a longer investment, just curious of your opinions.
0 · Reply
gimoozaabi
gimoozaabi Jul. 1 at 8:31 PM
$XERS here you go, stairs of the princess on her way to enter the paramount castle
0 · Reply
Aptos2020
Aptos2020 Jul. 1 at 7:34 PM
$XERS not that it matters to me, but do any of the chartists sense resistance points above 8 and where we stand on RSI?
0 · Reply